大学化学 >> 2023, Vol. 38 >> Issue (8): 85-94.doi: 10.3866/PKU.DXHX202208060

知识介绍 上一篇    下一篇

治疗COVID-19的小分子药物研究进展

袁博2, 冯辰昀1,3,*(), 袁耀锋1,*()   

  1. 1 福州大学化学学院, 福州 350108
    2 国家药品监督管理局南方医药经济研究所, 广州 510080
    3 南方科技大学化学系, 广东 深圳 518055
  • 收稿日期:2022-08-09 录用日期:2022-09-19 发布日期:2022-11-23
  • 通讯作者: 冯辰昀,袁耀锋 E-mail:454913648@qq.com;yaofeng_yuan@fzu.edu.cn
  • 基金资助:
    国家自然科学基金(22071025);中国高等教育学会2021年度理科专项课题(21LKYB07)

Research Progress on Small-Molecule Drugs for Treating COVID-19

Bo Yuan2, Chenyun Feng1,3,*(), Yaofeng Yuan1,*()   

  1. 1 College of Chemistry, Fuzhou University, Fuzhou 350108, China
    2 National Medical Products Administration Southern Medical Economy Institute, Guangzhou 510080, China
    3 Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, Guangdong Province, China
  • Received:2022-08-09 Accepted:2022-09-19 Published:2022-11-23
  • Contact: Chenyun Feng, Yaofeng Yuan E-mail:454913648@qq.com;yaofeng_yuan@fzu.edu.cn

RichHTML

29

PDF

1118

赞

摘要：

新冠肺炎(COVID-19)疫情全球大流行对社会发展和人类健康带来了较大的影响，虽然SARS-CoV-2疫苗的成功上市一定程度遏制了病毒的传播，但要真正结束SARS-CoV-2大流行，还是需要科学、可持续的治疗方法。小分子药物具有靶点明确、给药方式方便、易于大规模生产、较少引起免疫反应等优势，因此治疗新冠肺炎的小分子药物研发受到了科学界和产业界的关注。值得注意的是，在过去三年中，一些潜在的、药效优良的药物被发现，并在临床的实验中取得了较好的结果。为了更好地了解化学小分子药物对治疗新冠肺炎的作用，本文将介绍2020年以来此类小分子药物的研究进展，为该领域的药物研究提供一定的借鉴。

关键词: SARS-CoV-2, 小分子药物, RdRp, 阿兹夫定, PaxlovidTM

Abstract:

The COVID-19 pandemic has caused significant losses and suffering around the world. Although the SARS-CoV-2 vaccine has largely controlled the spread of the virus, the scientific and sustainable treatment of COVID-19 patients is still necessary to truly end the pandemic. Small-molecule drugs against COVID-19 have attracted the attention of the scientific community and industry owing to their unique advantages such as a simple delivery method, relatively high output, and immune response with lower probability. Fortunately, in the last three years, some potentially effective drugs have been proposed, and have achieved good results in clinical trials. This paper briefly introduces the research progress on small-molecule drugs since 2020 to provide reference for future SARS-CoV-2 research.

Key words: SARS-CoV-2, Small molecule drugs, RdRp, Azvudine, PaxlovidTM